Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company dedicated to developing life-changing medicines for patients with rare diseases, often addressing conditions with limited or no existing therapeutic options. The company's website is www.jazzpharmaceuticals.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Jazz Pharmaceuticals plc does
In the company’s own words
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company dedicated to developing life-changing medicines for patients with rare diseases, often addressing conditions with limited or no existing therapeutic options. The company's website is www.jazzpharmaceuticals.com.
Jazz operates a diversified portfolio of marketed products across three primary therapeutic areas: rare sleep disorders, rare epilepsies, and rare oncology. The company's lead products include Xywav, a low-sodium oxybate therapy for narcolepsy and idiopathic hypersomnia that generated $1.657 billion in net product sales in 2025 representing 41 percent of total net product sales; Epidiolex, a cannabidiol-based treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex that generated $1.059 billion in 2025 representing 26 percent of total net product sales; and Rylaze, an asparaginase therapy for acute lymphoblastic leukemia and lymphoblastic lymphoma that generated $402.9 million in 2025 representing 10 percent of total net product sales. Additional marketed products include Zepzelca for small cell lung cancer, Ziihera for HER2-positive biliary tract cancers, and Modeyso for diffuse midline glioma.
The company's strategy emphasizes strong commercial execution, pipeline expansion, and strategic acquisitions to complement its existing portfolio. Jazz maintains an efficient, scalable operating model with integrated global capabilities to reach patients worldwide. The company completed the acquisition of Chimerix in April 2025, adding Modeyso to its rare oncology portfolio. Jazz also divested Sativex to CNX Therapeutics in October 2025.
Jazz's business model focuses on rare diseases characterized by high unmet medical needs and concentrated patient populations, enabling efficient commercialization. The company leverages proprietary intellectual property, regulatory exclusivities including orphan drug designations, and established relationships with healthcare providers and payers. The oxybate franchise, including both Xywav and the legacy Xyrem product, represents a significant portion of revenues, though the company has successfully diversified its revenue base substantially over recent years through product launches and acquisitions.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- DUBLIN
- Fiscal year end
- December
- CIK
- 1232524
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Jazz Pharmaceuticals plc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Jazz Pharmaceuticals plc · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Jazz Pharmaceuticals plc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Jazz Pharmaceuticals plc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Jazz Pharmaceuticals plc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Jazz Pharmaceuticals plc's last four quarterly filings that the numbers alone won't show?”